Viaduktstr. 40
4051 Basel
Switzerland
Phone: +41 61 5647000
Fax: +41 61 5647090
http://www.resmed.com
info@resmed.ch
Manufacturers
Company Contacts
Department/ Name Address
ResMed Austria Medizintechnik GmbH Muthgasse 36, 1190 Wien, +43 1 803 4700, +43 1 803 4800
info@resmed.at
ResMed GmbH & Co. KG Fraunhoferstraße 16, 82152 Martinsried, +49 (0) 89 / 99 01 – 00, 0800 2 777 000 (Gebührenfreie Servicenummer), +49 (0) 89 / 99 01 – 10 55
reception@resmed.de
Company Figures
Number of employees 500-999
Year of foundation 1989
Area of business Electronical Equipment / Medical Technology
Language: German Language: English Company Profile
About Us.
ResMed (ASX: RMD and NYSE: RMD) is a leading developer, manufacturer and marketer of products for the screening, treatment and long-term management of sleep-disordered breathing (SDB) and other respiratory disorders.
ResMed operates in over 65 countries via 16 direct offices and a network of distributors with extensive knowledge and experience of local markets.
The ResMed Story
Formed in 1989
Primary purpose was to commercialize a device for treating obstructive sleep apnea (OSA), a major subset of sleep disordered breathing (SDB)
Developed in 1981 by Professor Colin Sullivan and colleagues at the University of Sydney, nasal continuous positive airway pressure (CPAP) provided the first successful noninvasive treatment of OSA
Since 1989, ResMed has maintained its focus on SDB
Operations have grown dramatically via introduction of a number of highly innovative product lines
The market
SDB affects around 20% of the adult population¹, making it as widespread as diabetes or asthma. However, awareness is low and we believe that about 90% of people who have OSA remain undiagnosed and untreated. Along with an increasing understanding of the morbidity and mortality caused by SDB, this discrepancy has created one of the fastest growing segments of the respiratory industry. ResMed is positioned to meet the growing challenges of this under-penetrated market.
1 Young et al. Am J Respir Crit Care Med. 2002; 165:1217-1239
Increasing awareness
ResMed is committed to increasing education and awareness of the serious health consequences of untreated SDB among both the general public and physicians. Our extensive geographical coverage allows us to work progressively towards this awareness. We have established ResMed Foundations in both Australia and the United States and are funding a public relations program (together with other industry participants) in several countries to publicize the dangers of undiagnosed SDB.
Understanding SDB
The term “sleep-disordered breathing” (SDB) includes a spectrum of respiratory disorders ranging in severity from snoring to OSA. OSA occurs when the airway temporarily collapses during sleep, preventing or restricting breathing for up to ten seconds or more. Such events can occur several hundred times a night severely disrupting sleep.
Untreated OSA can severely affect quality of life, health and mortality. Clinical research shows that it is linked strongly to a range of serious, even life-threatening, chronic diseases such as stroke, heart failure, hypertension, diabetes, obesity and coronary heart disease. Other links include preeclampsia in pregnant women, attention deficit disorder in children and increased traffic and workplace accidents.
Treatment
Widely accepted across the globe, positive airway pressure treatment is a highly effective, proven and popular way to treat OSA.
Involves wearing a mask or nasal pillows system connected to a small portable airflow generator that delivers air at positive pressure. The air pressure acts like an “air splint” to keep the airway open.
Continuing research and product development
We continue to invest approximately 6% of revenues in research and product development—that’s a growing dollar figure every year, demonstrating our commitment to continuing global leadership in sleep medicine based on our innovative technologies. ResMed’s team is focused on developing innovative therapies that increase patient comfort and convenience while improving health. As of December 2005 we had 582 patents and 401 design registrations, granted or pending worldwide.
ResMed recognized
In 2005 we made the BusinessWeek list of 100 Hot Growth Companies for the sixth time in seven years. We were also awarded Manufacturer of the Year for 2006 by the UK Association for Respiratory Technology & Physiology (ARTP) and, in Australia, won the Large Advanced Manufacturer Category of the 2005 Premier’s NSW Exporter of the Year Award. In addition, ResMed CEO Dr Peter Farrell was named Ernst & Young Entrepreneur Of The Year® 2005 US national award winner in the Health Sciences Category.
The ResMed team
Business success can be said to depend upon three key fundamentals—people, products and profits—and that without a good team the other two just aren’t possible. ResMed has a team of over 2000 people based around the globe. Everyone in our team is working to help the millions of people suffering from SDB and other respiratory disorders, to educate the medical community and public about the dangers of untreated SDB, to strengthen our global operations and to deliver the very best products to our SDB patients.
In addition, we have a senior management team with extensive experience in the SDB field and the medical device industry in general. We also leverage the knowledge and expertise of our Medical Advisory Board, which consists of leading SDB experts.